Novartis | NOVN - Ebit

Aktienkurs
118.82
Täglich Wechseln
1.40 1.19%
Monatlich
-0.57%
Jährlich
31.03%
Q2 Prognose
119.13




Ebit Veränderung Datum
AbbVie USD 5.81B 4.36B 2025-12
Alcon AG USD 317M 17M 2025-12
Almirall EUR 30.23M 12.8M 2025-12
Amgen USD 3.96B 464M 2025-12
AstraZeneca USD 2.97B 4.48B 2025-12
Autolus Therapeutics Ltd USD -72.47M 845K 2025-12
Bayer EUR 1.11B 1.51B 2025-12
Biogen USD 659.6M 157M 2025-09
Bristol-Myers Squibb USD 3.47B 567M 2025-12
Eli Lilly USD 8.99B 1.57B 2025-12
Fresenius EUR 713M 139M 2025-12
Fresenius Medical Care EUR 663M 213.06M 2025-12
Galapagos EUR 780.56M 822.23M 2025-12
Genmab DKK 260M 199M 2025-12
Gilead Sciences USD 2.96B 551M 2025-12
GlaxoSmithKline GBP 1.44B 1.35B 2025-12
GRIFOLS EUR 352.11M 20.18M 2025-09
Hikma Pharmaceutical USD 348M 31M 2025-12
J&J USD 6.62B 1.51B 2026-03
Lonza CHF 673M 54M 2025-06
Merck EUR 474M 738M 2025-12
Merck USD 6.24B 1.32B 2025-12
Novartis USD 4.06B 530M 2025-12
Novartis USD 4.06B 413M 2025-12
Novo Nordisk DKK 32.38B 1.7B 2025-12
Orion EUR 328.1M 207.1M 2025-12
Pfizer USD 4.65B 71M 2025-12
Philips EUR 719M 390M 2025-12
Recordati EUR 278.23M 112.58M 2025-12
Regeneron Pharmaceuticals USD 898.6M 211.3M 2025-12
Roche Holding CHF 9.56B 2.1B 2025-12
Sanofi EUR 1.7B 2.17B 2025-12
UCB EUR 1.29B 571M 2025-12